Introduction
============

Traumatic brain injury (TBI) is a leading contributor to rates of mortality and permanent disability in individuals aged \<45 years ([@b1-mmr-14-04-3690],[@b2-mmr-14-04-3690]). Almost 2,000,000 individuals sustain a TBI annually in the USA, contributing to one third of all cases of injury-associated mortality ([@b3-mmr-14-04-3690]). In China, TBI accounts for between 38.7 and 57.3% of cases of road traffic accident-associated mortality ([@b4-mmr-14-04-3690]). The costs of the long-term treatment and rehabilitation following TBI constitute a considerable burden on society ([@b5-mmr-14-04-3690]), and its therapeutic efficacy remains unsatisfactory as its pathogenesis is driven by complex and interactive mechanisms ([@b6-mmr-14-04-3690]).

Following TBI, secondary brain injury is the leading cause of TBI-associated mortality in hospital inpatients ([@b7-mmr-14-04-3690]). Free radical-induced oxidative damage occurs rapidly and and is of primary importance during secondary pathophysiological cascades. During secondary brain injury in TBI, the brain is vulnerable to oxidative stress due to the high rate of oxidative metabolic activities, the abundance of polyunsaturated fatty acids and the relatively low levels of antioxidant enzyme activity ([@b8-mmr-14-04-3690]). Morphological responses and neurobehavioral deficits deteriorate under the effects of oxidative neurodegeneration ([@b9-mmr-14-04-3690]). The dynamic equilibrium between oxidants and antioxidants is disrupted following cerebral injury by the excessive consumption of antioxidants or accumulation of reactive oxygen species (ROS), or the two in combination ([@b10-mmr-14-04-3690]). When the injured areas produce excess ROS following brain injury, superoxide (O~2~·) and nitric oxide (·NO) radicals are produced first, which become more potent oxidants through a series of reactions and metabolism, including peroxynitrite (ONOO·), hydroxyl (·OH), carbonate (CO~3~·) and nitrogen dioxide (·NO~2~) radicals ([@b11-mmr-14-04-3690]). These byproducts further oxidize proteins, lipids, sugars and nucleotides ([@b12-mmr-14-04-3690]--[@b14-mmr-14-04-3690]). The above data demonstrate a significant early contribution of oxidative damage in the secondary injury response in TBI, reinforcing the requirement of improved antioxidant therapies.

Hydroxysafflor yellow A (HSYA; [Fig. 1](#f1-mmr-14-04-3690){ref-type="fig"}), a flavonoid compound extracted from *Carthamus tinctorius* L. (Asteraceae), has been used as an active marker compound for controlling the quality of safflower in the Chinese Pharmacopoeia ([@b15-mmr-14-04-3690]). Previous studies have indicated that HSYA has cerebral protective effects ([@b16-mmr-14-04-3690]) by reducing protein oxidation/nitration and lipid peroxides ([@b12-mmr-14-04-3690],[@b13-mmr-14-04-3690]), suppressing inflammatory responses ([@b17-mmr-14-04-3690]) and attenuating breakdown of the blood-brain barrier (BBB) ([@b12-mmr-14-04-3690]). Previous studies have also reported that HSYA may offer potential as a therapeutic strategy to improve outcomes following TBI ([@b18-mmr-14-04-3690],[@b19-mmr-14-04-3690]). However, no previous investigations have focused on the mechanism underlying the antioxidant activities of HSYA in a rat model of TBI. Thus, the present study aimed to determine the antioxidant effects of HSYA on TBI in rats.

In the present study, to determine the absorption of HSYA for investigation of the underlying antioxidant effects of HSYA in TBI, HSYA was identified in the brain tissues of TBI-induced rats using an ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method. Subsequently, the state of oxidative stress in the TBI rat model following the administration of HSYA was estimated by determining the levels of superoxide dismutase (SOD), malondialdehyde (MDA) and catalase (CAT), in addition to the ratio of glutathione (GSH)/glutathione disulfide (GSSG).

Materials and methods
=====================

Plant materials and chemicals
-----------------------------

HSYA (purity \>98%) was purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Gradient grade methanol for liquid chromatography was supplied by Merck Millipore (Darmstadt, Germany). Formic acid was obtained from Sinopharm Chemical Reagent Company (Shanghai, China) and high purity water was obtained from Wahaha Co., Ltd. (Hangzhou, China). The assay kits for SOD, MDA, CAT, GSH and GSSG, and Bradford protein were obtained from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). All other reagents were of analytical grade.

Animals and surgical procedure
------------------------------

Healthy male Sprague-Dawley (SD) rats (weighing between 200 and 250 g, age, 8--10 weeks) were supplied by the Laboratory Animal Research Center of Central South University (Changsha, China). The rats were housed in an environmentally controlled breeding room (22--25°C; 12-h light/dark cycle; 50±10% humidity) with access to a normal standard chow diet and tap water *ad libitum*. The animals were maintained under these conditions for at least 1 week, following which they were fasted for 12 h with free access to water prior to each experiment. All animal experiments were approved by the Central South University Animal Ethics Committee and conformed to the Guidelines for the Care and Use of Laboratory Animals.

The controlled cortical impact (CCI) model with TBI was established using an electronic controlled pneumatic impact device (TBI 0310; Precision Systems and Instrumentation LLC, Fairfax Station, VA, USA) under 3% pentobarbital anesthesia (50 mg/kg), which was equipped with a hard stop Bimba cylinder (Bimba Manufacturing, Monee, IL, USA) and an impactor tip (external diameter, 5 mm); this is an approved instrument for the TBI model. The parameters of the apparatus were as follows: Depth of impact, 5.00 mm from the cortical surface; impact velocity, 6.00 m/sec; dwell time, 500 msec. The body temperature of the rats was monitored throughout surgery, and a heated cage was used to maintain body temperature at 37.0±0.5°C. Following surgery, the animals recovered fully in \~20 min, and the survival rate following surgery was \>90%. A total of 96 SD rats were randomly divided into the following four groups for the efficacy experiment: i) Vehicle control group, rats with TBI were intragastrically administered with 4 ml normal saline vehicle (0.9% NaCl); ii) sham operation group, rats underwent the same surgical procedures, but without trauma to the cerebral cortex; iii) 10 mg/kg HSYA treatment group, rats were orally administered with 10 mg/kg HSYA following trauma; iv) 30 mg/kg HSYA group, rats were orally administered with 30 mg/kg HSYA following trauma. Each group of rats were sacrificed by decapitation in an ice bath at 6, 12 and 24 h following intragastric administration. The ipsilateral cortex was immediately removed, placed in an ice bag and stored at −80°C for biochemical assays, which were performed within 1 month.

Detection of HSYA in brain tissues using the UPLC-MS/MS) method
---------------------------------------------------------------

Following the oral administration of HSYA in rats subjected to TBI, the absorption of the compound in the brain tissue was determined by comparing the retention times and ion peaks with the authentic reference using the UPLC-MS/MS method.

The Acquity TQD UPLC-MS/MS system (Waters Corporation, Milford, MA, USA), consisting of Acquity UPLC online SPE manager (OSM), Acquity UPLC binary solvent manager, Acquity UPLC column manager, Acquity UPLC sample manager, Acquity TQ detector, masstrack online SPE cartridges and Acquity UPLC online SPE manager software (MassLynx) was used. Analyses were performed under an electrospray ionization source, which was operated in the negative mode (ESI^−^). A Waters Acquity UPLC BEH C~8~ (2.1×100 mm; 1.7 *µ*m) column with methanol (A) and 0.1% formic acid in water (B) was used at a flow rate of 0.3 ml/min to establish the elution gradient (A:B ratios: 0 min, 10:90; 5 min, 60:40; 6 min, 90:10; 7 min, 90:10; 8 min, 10:90). The column temperature was set at 30°C. The injection volume was 5 *µ*l using full-loop mode. The detection wavelengths of the photodiode array detector were set at 200--600 nm. For MS/MS detection, the following parameters were used: Temperature of source gas (nitrogen), 110°C; desolvation gas (nitrogen) flow, 650 l/h at 365°C; capillary voltage, 2.5 KV; cone voltage, 26 V; cone gas flow, 50 l/h; collision gas (argon) flow, 0.2 ml/min. Detection was performed in the multiple reaction monitoring mode (MRM).

The HSYA (30 mg/kg) was administered to the TBI rats, and the whole brain was rapidly removed following decapitation 30 min later. The surface blood products were cleared with ice-cold ddH~2~O, and the samples were dissected and homogenized in 4 ml ice-cold methanol using a TissueLyser LT homogenizer (Qiagen GmbH, Hilden, Germany). The homogenates were centrifuged at 1,500 × *g* at 4°C for 10 min, and the supernatant was collected separately for evaporation to dryness under nitrogen at 37°C. Each dry extract was dissolved in 200 *µ*l methanol (20%) and then centrifuged at 7,500 × *g* at 4°C for 15 min. The upper layer was filtered through a 0.22 *µ*m nylon filter, and 5 *µ*l was injected automatically to UPLC-MS/MS for analysis.

Estimation of antioxidant and oxidative status
----------------------------------------------

The stored cortices were weighed, dissected and homogenized with nine volumes (1:9, w/v) of ice-cold normal saline in a homogenizer (TissueLyser LT; Qiagen, GmbH). The homogenates were centrifuged at 1,500 × *g* at 4°C for 15 min. The supernatants were used to measure the oxidative product contents, antioxidant enzyme activities and redox status, according to the manufacturer\'s protocols for the reagent kits (Nanjing Jiancheng Bioengineering Institute). Tissue protein concentrations were measured using the Bradford method ([@b20-mmr-14-04-3690]).

The cortical levels of MDA were estimated using the thiobarbituric acid (TBA) method, as described by Zhao *et al*, with minor modifications ([@b21-mmr-14-04-3690]). According to the manufacturer\'s protocol, the supernatant and TBA were mixed together and incubated at 95°C for 40 min. The reaction mixture was cooled to room temperature under flowing water and centrifuged at 1,750 × *g* for 10 min at 4°C. The upper layer was used to determine the change in absorbance on a spectrophotometer at 532 nm.

In measuring the activities of the antioxidant enzymes, the supernatant obtained was used to determine the activities of SOD and CAT. The detailed procedures were in accordance with the instructions of the assay kits supplied by Nanjing Jiancheng Bioengineering Institute. The absorbance of the test solution was measured at a wavelength of 450 nm for SOD activity and 405 nm for CAT activity. The activities of SOD and CAT were corrected with protein quantity and expressed as the fold change relative to the control, as U/mg of protein.

The levels of GSH and GSSG in the cortices were determined to assess the redox status. The protocol, according to the specification of the GSH/GSSG assay kit (Nanjing Jiancheng Bioengineering Institute), was previously reported by Zhao *et al* ([@b21-mmr-14-04-3690]). The absorbance was recorded at 405 nm on a spectrophotometer and then used to calculate the GSH/GSSG ratio.

Statistical analysis
--------------------

All data were analyzed using SPSS 15.0 software (SPSS, Inc. Chicago, IL, USA). One-way analysis of variance and Dunnett\'s *t*-test were used to determine the significant differences between the four groups. All parameters are expressed as the mean ± standard deviation. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Detection of HSYA using UPLC-MS/MS
----------------------------------

The overall intra- and inter-day variations were \<5% for HSYA, and the method was reproducible with good precision. The accuracy assessments were performed using recovery assessment, and the recovery of all compounds was \>90%. These results suggested that the UPLC-MS/MS method was suitable for the detection of HSYA. As shown in [Fig. 2](#f2-mmr-14-04-3690){ref-type="fig"}, the predominant mass transitions of HSYA were m/z 611.18→491.04, according to the UPLC-MS/MS method. The precursor ion was detected at m/z 611 \[M--H\]^−^. In the production mass spectra of \[M--H\]^−^, m/z 491 was the prominent fragment ion. HSYA was identified in the extracts or biopsies based on its retention time (2.74±0.02 min), and characteristic \[M--H\]^−^ ion (m/z 611.18) and fragment ions (m/z 491.04). Representative MRM chromatograms of the brain tissues from the untreated (drug-free), HYSA-treated and TBI+HYSA administration rats are shown in [Fig. 3A--C](#f3-mmr-14-04-3690){ref-type="fig"}, respectively.

Effects of antioxidant assay
----------------------------

As shown in [Fig. 4](#f4-mmr-14-04-3690){ref-type="fig"}, significantly higher levels of MDA were measured in the brains of the TBI (vehicle) rats, compared with the sham group (P\<0.01). Treatment with HSYA (10 and 30 mg/kg) significantly decreased the levels of MDA at different time points (6, 12 and 24 h), compared with the vehicle (P\<0.05 and P\<0.01). The maximum alteration was observed at 24 h.

Compared with the sham treatment group, cerebral injury in the TBI rats led to a significant decline in the activities of SOD and CAT, as shown in [Fig. 5](#f5-mmr-14-04-3690){ref-type="fig"} (P\<0.01). The administration of HSYA (10 and 30 mg/kg) caused a significant increase in the levels of SOD at different time points (6, 12 and 24 h), compared with the vehicle-treated group (P\<0.05 and P\<0.01), particularly following treatment with the high dose of HSYA (30 mg/kg). The activity of CAT increased significantly 12 h following treatment with the low dose of HSYA (10 mg/kg), compared with the vehicle treatment (P\<0.05). Following treatment with a high dose of HSYA (30 mg/kg), the activities of CAT were significantly increased at all time points (6, 12 and 2 h), compared with the vehicle treatment (P\<0.05 and P\<0.01).

As shown in [Table I](#tI-mmr-14-04-3690){ref-type="table"}, brain injury reduced the levels of GSH and the GSH/GSSG ratios, and simultaneously increased levels of GSSG (all P\<0.01), compared with the sham group. The treatments with HSYA (10 and 30 mg/kg) significantly increased the levels of GSH and GSH/GSSG ratios, and decreased the levels of GSSG in the cerebral tissues of the TBI rats, compared with the vehicle group.

Discussion
==========

The present study demonstrated that, according to the UPLC-MS/MS method, HSYA was absorbed in the brain tissues of TBI rats. Treatment of the TBI rats with HSYA significantly alleviated the imbalance between oxidants and antioxidants, resulting in further neuroprotective effects. HSYA increased the activities of SOD and CAT, the level of GSH and the GSH/GSSG ratio. In addition, HSYA concomitantly decreased the levels of MDA and GSSG. The above preliminary data provided evidence suggesting that HSYA offers potential to be utilized as a neuroprotective drug for TBI.

To establish a link between the absorbed chemical compound and its biological activity, HSYA was detected in the brain tissues of TBI rats using the UPLC-MS/MS method. If no evidence of absorption is found, any investigation of an effect-associated component is most likely to be incorrect ([@b22-mmr-14-04-3690]). Thus, in the present study, a sensitive and accurate UPLC-MS/MS method was successfully developed to detect HSYA in the brain tissues of the TBI rats. The pretreatment of samples makes this method easy to perform in a short period of time, and the method of analysis conforms to the criteria for validation of the UPLC-MS/MS method including calibration curve, intra- and inter-day precisions and relative standard deviation of recovery ([@b19-mmr-14-04-3690]). According to the mass spectrum of the HSYA, as shown in [Fig. 2](#f2-mmr-14-04-3690){ref-type="fig"}, two mass transitions, which followed were 611→491.04 m/z and 611→325.06 m/z. These two MRM chromatograms were used to record the response. The HSYA in the biopsies were identified by comparing the retention time and ion peaks ([Fig. 3](#f3-mmr-14-04-3690){ref-type="fig"}). The results provided evidence that HSYA was absorbed in the brains of the TBI rats. The detection of this bioactive compound may assist in elucidating the direct pharmacological actions of HSYA for the treatment of TBI, and enables further investigation of the effects of HSYA on oxidative stress in the rat model of TBI.

HSYA is a hydrophilic drug with low oral bioavailability, belonging to the biopharmaceutics classification system III class of drugs ([@b23-mmr-14-04-3690],[@b24-mmr-14-04-3690]). A previous study confirmed that HSYA can cross the BBB ([@b19-mmr-14-04-3690]) and, consequently, HSYA has been administered via injection in several studies for investigating the treatment of cerebral diseases ([@b18-mmr-14-04-3690],[@b25-mmr-14-04-3690],[@b26-mmr-14-04-3690]). Of note, following TBI, small molecules (286--10,000 Da) are able to enter the brain up to a few days following injury due to BBB disruption ([@b27-mmr-14-04-3690]). Therefore, HSYA, with a molecular weight of 611 Da, is more readily absorbed into the brains of TBI rats, compared with normal rat ([@b28-mmr-14-04-3690]). In addition, the period of potential secondary damage from barrier disruption and the period during which HSYA has direct access to the injured brain may be longer than previously suggested ([@b27-mmr-14-04-3690]). This leads to the accumulation of higher levels of HSYA in the brain tissues of TBI rats, which may have neuroprotective effects. Thus, the disruption of the BBB following TBI enables HSYA to cross the barrier and exert antioxidative effects.

Oxidative stress is important in the pathogenesis of secondary brain injury following TBI ([@b29-mmr-14-04-3690]). Brain tissue is enriched with fatty acids, which are readily peroxidized, consumes a substantial proportion (20%) of total oxygen consumption for its relatively low weight (2%), and has limited antioxidant defenses ([@b30-mmr-14-04-3690]). In addition, the cerebral metabolic rate is 7.5-fold higher than the average metabolic rate ([@b31-mmr-14-04-3690]). Due to its higher metabolic rate and lipid content, the brain is considered to be particularly sensitive to oxidative damage following TBI. TBI generally results in tardive neurological dysfunction and death through the processes of secondary injury ([@b32-mmr-14-04-3690],[@b33-mmr-14-04-3690]). It is associated with a mechanism involving excess excitatory amino acids ([@b28-mmr-14-04-3690]), ionic imbalance ([@b34-mmr-14-04-3690]), anomalous proteolytic enzyme activity ([@b35-mmr-14-04-3690]), a low level of ATP ([@b36-mmr-14-04-3690]) and oxidative stress. Among these, continued oxidative stress is a significant contributor to the deterioration of neurological function ([@b37-mmr-14-04-3690]). Neurological function is vulnerable to injury by oxidative stress as its rate of oxygen consumption is high, nerve cells are not readily replenished, and the high levels of polyunsaturated fatty acids in the brain are targets of the lipid peroxidation initiated by ROS ([@b38-mmr-14-04-3690]). The accumulated ROS include superoxide (O~2~·), hydroxyl radical (·OH), hydrogen peroxide (H~2~O~2~) and hypochlorous acid (HOCl), which induces protein oxidation, inhibits the mitochondrial electron transport chain, cleaves DNA and leads to the peroxidation of cellular and vascular structures ([@b39-mmr-14-04-3690]). The above processes lead to hypoperfusion, disruption of axonal guidance, disordered metabolism and brain edema ([@b40-mmr-14-04-3690]).

MDA is the end product of membrane lipid peroxidation, which is generated from cellular membrane damage in oxidative stress ([@b41-mmr-14-04-3690]). Therefore, it is widely considered to be a valuable index for measuring the extent of oxidative stress. SOD and CAT enzymes are crucial mediators in scavenging rapidly generated oxygen free radicals following TBI. SOD is a first line anti-oxidative enzyme, which is responsible for the defense mechanism against ROS and other superoxide anion-free radicals ([@b42-mmr-14-04-3690]). SOD first catalyzes the transformation of superoxide radicals to H~2~O~2~ ([@b43-mmr-14-04-3690]), following which CAT transforms H~2~O~2~ into H~2~O and O~2~ ([@b44-mmr-14-04-3690]). The GSH system is well known to protect cells against oxidative damage in the pivotal role of redox homeostasis. It consists of reduced and oxidized forms of GSH. GSH is a predominant intracellular nonenzymatic antioxidant in tissues. During the processes of oxidative damage, GSH binds directly to oxygen free radicals to facilitate the conversion of H~2~O~2~, to then become GSSG ([@b45-mmr-14-04-3690],[@b46-mmr-14-04-3690]). The measurement of GSH/GSSG is a useful indicator of oxidative stress and can be used to monitor antioxidant effects ([@b46-mmr-14-04-3690]).

Accordingly, the present study determined the levels of MDA, SOD and CAT, and the GSH/GSSG ratio to investigate the antioxidant effects. The results of the present study showed that HSYA treatment significantly prevented the increases in the levels of MDA, SOD and CAT. Furthermore, the levels of GSH were increased and the levels of GSSG were decreased following treatment with HSYA, compared with those in the vehicle group. The elevation of the GSH/GSSG ratio in the present study also reflects the anti-oxidative effect of HSYA. These results suggested that HSYA attenuated the excessive formation of free radicals secondary to TBI. Further investigations are required to investigate the detailed mechanisms of the signaling pathway underlying the effects of HSYA on brain cells against oxidative stress *in vivo* and *in vitro*.

In conclusion, treatment with the absorbed bioactive compound HSY attenuated oxidative injury to markedly inhibit neuronal injury following TBI, indicating that HSYA offers potential in TBI treatment as a neuroprotective therapy for the prevention of oxidative stress. The present study presented a canonical method to elucidate the mechanism of action in herbal chemicals, and suggested that HSYA may be a promising therapeutical compound for the treatment of TBI.
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![Detection of HSYA in brain tissues of TBI rats using ultra-high performance liquid chromatography with tandem mass spectrometry. Representative multiple reaction monitoring chromatograms of HSYA in (A) untreated brain tissue, (B) normal brain tissue treated with reference HSYA and (C) brain tissue post-TBI and 30 min following intragastric administration of HSYA (30 mg/kg). HYSA, hydroxysafflor yellow A; TBI traumatic brain injury.](MMR-14-04-3690-g02){#f3-mmr-14-04-3690}

![Effects of HSYA (10 and 30 mg/kg) on the levels of MDA in rat brain tissues at different time points. Values are expressed as the mean ± standard deviation. ^\#^P\<0.01, compared with the sham group at the same time point, ^\*^P\<0.05, compared with the vehicle group at the same time point, \*\*P\<0.01, compared with the vehicle group at the same time point. HYSA, hydroxysafflor yellow A; MDA, malondialdehyde.](MMR-14-04-3690-g03){#f4-mmr-14-04-3690}

![Effects of HSYA (10 and 30 mg/kg) on the levels of SOD and CAT. The levels of (A) SOD and (B) CAT in the rat brain tissues were examined at different time points. Values are expressed as the mean ± standard deviation. ^\#^P\<0.01, compared with the sham group at the same time point; ^\*^P\<0.05, compared with the vehicle group at the same time point; ^\*\*^P\<0.01, compared with the vehicle group at the same time point. HYSA, hydroxysafflor yellow A; SOD, superoxide dismutase; CAT, catalase.](MMR-14-04-3690-g04){#f5-mmr-14-04-3690}

###### 

Effect of HSYA on the levels of reduced and oxidized GSH in brain tissues of rats 6, 12 and 24 h following traumatic brain injury.

  Group           6 h                                                        12 h                                                       24 h                                                                                                                                                                                                                                                                                                                                                            
  --------------- ---------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------
  Sham            91.98±7.09[a](#tfn2-mmr-14-04-3690){ref-type="table-fn"}   30.61±3.27[b](#tfn3-mmr-14-04-3690){ref-type="table-fn"}   3.06±0.57[a](#tfn2-mmr-14-04-3690){ref-type="table-fn"}   92.78±6.49[a](#tfn2-mmr-14-04-3690){ref-type="table-fn"}   31.44±1.09[a](#tfn2-mmr-14-04-3690){ref-type="table-fn"}   2.96±0.30[a](#tfn2-mmr-14-04-3690){ref-type="table-fn"}   93.12±4.97[a](#tfn2-mmr-14-04-3690){ref-type="table-fn"}   31.61±1.93[a](#tfn2-mmr-14-04-3690){ref-type="table-fn"}   2.96±0.33[a](#tfn2-mmr-14-04-3690){ref-type="table-fn"}
  Vehicle         68.90±6.41                                                 41.43±2.72                                                 1.75±0.13                                                 66.30±7.25                                                 40.43±2.93                                                 1.64±0.16                                                 60.55±6.82                                                 42.77±3.22                                                 1.42±0.16
  10 mg/kg HSYA   72.29±3.56[c](#tfn4-mmr-14-04-3690){ref-type="table-fn"}   31.16±3.68                                                 2.18±0.29[c](#tfn4-mmr-14-04-3690){ref-type="table-fn"}   79.69±6.68[c](#tfn4-mmr-14-04-3690){ref-type="table-fn"}   31.64±2.54[c](#tfn4-mmr-14-04-3690){ref-type="table-fn"}   2.53±0.26[c](#tfn4-mmr-14-04-3690){ref-type="table-fn"}   68.02±6.94[b](#tfn3-mmr-14-04-3690){ref-type="table-fn"}   36.27±2.79[a](#tfn2-mmr-14-04-3690){ref-type="table-fn"}   2.21±0.23[a](#tfn2-mmr-14-04-3690){ref-type="table-fn"}
  30 mg/kg HSYA   80.07±6.84[c](#tfn4-mmr-14-04-3690){ref-type="table-fn"}   34.78±4.62[c](#tfn4-mmr-14-04-3690){ref-type="table-fn"}   2.66±0.35[c](#tfn4-mmr-14-04-3690){ref-type="table-fn"}   82.13±7.62[c](#tfn4-mmr-14-04-3690){ref-type="table-fn"}   32.41±2.28[b](#tfn3-mmr-14-04-3690){ref-type="table-fn"}   2.86±0.36[a](#tfn2-mmr-14-04-3690){ref-type="table-fn"}   84.19±7.92[a](#tfn2-mmr-14-04-3690){ref-type="table-fn"}   33.24±3.08[b](#tfn3-mmr-14-04-3690){ref-type="table-fn"}   2.68±0.13[a](#tfn2-mmr-14-04-3690){ref-type="table-fn"}

Each value is presented as the mean ± standard deviation (n=6).

P\<0.001, compared with the vehicle group;

P\<0.01 and

P\<0.05, compared with the vehicle group. HYSA, hydroxysafflor yellow A; Sham, sham-surgery (control), Vehicle, orally administered with vehicle; 10 mg/kg HSYA, orally administered with 10 mg/kg HSYA; 30 mg/kg HSYA, orally administered with 30 mg/kg HSYA. GSH, glutathione; GSSG, glutathione disulfide.
